Sharemaestro company-news research for Merck KGaA (MRCK), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

VIE Austria Provisional evidence

Company news sentiment

Latest MRCK news and sentiment

Merck KGaA

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report RSS feed
30-day score50Neutral is 50
Early balanced news score 17/100 evidence confidence 100% direct company focus 1 current stories across 1 publishers
Latest weekly closeEUR 135.45week of 4 Sep 2026
Main news subjectEarnings72/100 share of current news
News data statusPartial0 duplicate stories removed

Current company news

Early balanced news score

1 company-specific story are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone83/100 Published 30-day score50/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Earnings call transcript: Merck KGaA beats Q1 2026 expectations, stock rises 6% Investing.com · 12 Aug 2026 02:16 · Source lookup

What supports the score

Direct evidence

1 current stories are mapped specifically to MRCK.

What limits the score

Source breadth

Only 1 publisher currently contribute to the measured read.

Confidence

Confidence is 17/100, below the threshold for a firm score.

50/100
News scoreEarly balanced news score
17/100
Confidencethin evidence
100%/100
Company news1 company stories
N/A/100
Story agreementrequires at least 2 stories

News history

Daily score and story count over 30 days

Daily weighted evidence
12 Aug: 1 stories 12 Aug: tone 83, 1 stories 95505
11 Aug26 Aug09 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence0
0.009 after freshness weighting
Source breadth20
1 independent publishers
Company relevance100
share tied directly to this company
Freshness1
recency-weighted evidence
Agreement0
requires at least 2 stories
Publisher mix0
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks15 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Mar 2026: close 106.411087, indexed 100.020 Mar 2026: close 102.244827, indexed 96.127 Mar 2026: close 103.02906, indexed 96.803 Apr 2026: close 107.048271, indexed 100.610 Apr 2026: close 110.087189, indexed 103.517 Apr 2026: close 116.017975, indexed 109.024 Apr 2026: close 109.449997, indexed 102.901 May 2026: close 110.5, indexed 103.808 May 2026: close 112.849998, indexed 106.115 May 2026: close 116.75, indexed 109.722 May 2026: close 128.850006, indexed 121.129 May 2026: close 130.649994, indexed 122.805 Jun 2026: close 138.0, indexed 129.712 Jun 2026: close 133.600006, indexed 125.619 Jun 2026: close 132.899994, indexed 124.926 Jun 2026: close 145.0, indexed 136.303 Jul 2026: close 145.550003, indexed 136.810 Jul 2026: close 140.149994, indexed 131.717 Jul 2026: close 135.600006, indexed 127.424 Jul 2026: close 139.899994, indexed 131.531 Jul 2026: close 143.800003, indexed 135.107 Aug 2026: close 144.5, indexed 135.814 Aug 2026: close 136.350006, indexed 128.121 Aug 2026: close 137.0, indexed 128.728 Aug 2026: close 139.649994, indexed 131.204 Sep 2026: close 135.449997, indexed 127.3 15 May 2026: news score 50, close 116.75, 1 stories5022 May 2026: news score 50, close 128.850006, 1 stories29 May 2026: news score 50, close 130.649994, 1 stories05 Jun 2026: news score 50, close 138.0, 1 stories5026 Jun 2026: news score 51, close 145.0, 2 stories03 Jul 2026: news score 50, close 145.550003, 3 stories10 Jul 2026: news score 50, close 140.149994, 4 stories5017 Jul 2026: news score 54, close 135.600006, 8 stories24 Jul 2026: news score 54, close 139.899994, 13 stories31 Jul 2026: news score 54, close 143.800003, 13 stories5407 Aug 2026: news score 55, close 144.5, 17 stories14 Aug 2026: news score 59, close 136.350006, 16 stories21 Aug 2026: news score 54, close 137.0, 12 stories5428 Aug 2026: news score 52, close 139.649994, 7 stories04 Sep 2026: news score 51, close 135.449997, 4 stories51 Price index 141.7 116.4 91.2 News score 100 50 0
13 Mar09 Jun04 Sep
Weekly close, indexedSentiment score
26-week price+27.3%latest close 135.45
News score change+1first to latest comparable week
One-week response-3.0%Price reacting lower
Fair-value position+2.1%Near fair-value range
WeekNews scoreCloseWeekly move
04 Sep 202651EUR 135.449997-3.0%
28 Aug 202652EUR 139.649994+1.9%
21 Aug 202654EUR 137.0+0.5%
14 Aug 202659EUR 136.350006-5.6%
07 Aug 202655EUR 144.5+0.5%
31 Jul 202654EUR 143.800003+2.8%
24 Jul 202654EUR 139.899994+3.2%
17 Jul 202654EUR 135.600006-3.2%
Provisional evidence

News subjects

What is shaping the score

Earnings
Earnings831 stories · 100%

Source mix

Where the evidence comes from

0/100 independence
Investing.com831 stories · 100%

Recurring subjects

Subjects appearing most often

Current evidence

Topic structure will appear when classified tags are present in the current feed.

Earlier readings

How the score has changed

18 comparable readings · 116 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+050 to 50 · Broadly stable
Observed range47–6050 is the neutral baseline
Evidence depth2stories at latest stored reading · +1
Confidence16/100Provisional · +16
13 May50 neutral06 Sep 19:32
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
06 Sep 19:3250-1016/100 (-20)2 (-15)Provisional
12 Aug 23:5960+536/100 (0)17 (0)Provisional
06 Aug 23:5955+836/100 (+4)17 (+2)Provisional
04 Aug 23:5947-632/100 (+10)15 (+1)Provisional
02 Aug 23:5953-122/100 (-6)14 (+1)Provisional
30 Jul 23:5954+228/100 (+6)13 (+1)Provisional
29 Jul 23:5952-222/100 (-8)12 (-1)Provisional
23 Jul 23:5954+030/100 (+1)13 (+3)Provisional

Source headlines

The news behind the score

Showing 1-1 of 1

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#183Tone
Investing.comDirect company coverageScored from headlineSource lookup

Earnings call transcript: Merck KGaA beats Q1 2026 expectations, stock rises 6%

Published
12 Aug 2026 02:16
News subject
Earnings
Why this score
Beat expectations, Operating growth
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
High · 64/100
30-day weight
100% of the score · 27.7d old
Duplicates
1 consolidated

Earlier company news

MRCK news archive

Showing 1-22 of 22 stored headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Aug 06 2026
finance.yahoo.comArchivedPositive tone

Merck KGaA (MKGAF) (Q2 2026) Earnings Call Highlights: Robust Growth and Raised Guidance Signal ...

This article first appeared on GuruFocus. Net Sales: Increased from EUR5,255 million in Q2 2025 to EUR5,434 million in Q2 2026, with organic sales growth of 4.1%. EBITDA pre: Increased from EUR1.46 billion to EUR1.6 billion, with organic growth of 9.3% and reported growth of 9.4%. EBITDA pre Margin: Expanded by 1.6 percentage points year-over-year to 29.4%. EPS pre: Increased by 6.9% to EUR2.16. Operating Cash Flow: Increased by 6.7% to EUR605 million. Net Financial Debt: Increased to EUR9.2 billion as of June 30, mainly due to dividend payment. Life Science Sales: Grew organically by 8% in Q2

Dividend PaymentsEarningsFda ApprovalGuidanceM ASemiconductors
Published
6 Aug 2026 20:04
Catalyst
Guidance
Coverage
Direct company
Duplicates
1 consolidated
Jul 29 2026
finance.yahoo.comArchivedNeutral tone

Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development

Evinova's full Study Designer with AI suite will be leveraged by Merck KGaA, Darmstadt, Germany to shape future product innovations and accelerate industry-wide transformation BAAR, Switzerland, July 29, 2026--(BUSINESS WIRE)--Evinova, a global leader in AI-native clinical development technology, today announced a new multi-year strategic collaboration to accelerate global clinical development with Merck KGaA, Darmstadt, Germany, a leading science and technology company. Merck KGaA, Darmstadt, Germany will adopt the end-to-end capabilities of the Evinova AI-Native platform covering all modules

AIBiotechClinical DevelopmentPharma
Published
29 Jul 2026 09:00
Catalyst
Deals and strategy
Coverage
Direct company
Duplicates
1 consolidated
Jul 23 2026
finance.yahoo.comArchivedPositive tone

Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the Upgrade

Merck KGaA (MKKGY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zac

EarningsEarnings EstimateEstimate RevisionsInstitutional InvestorsRatingsUpgrade Downgrade
Published
23 Jul 2026 17:00
Catalyst
Analyst action
Coverage
Direct company
Duplicates
1 consolidated
Jul 23 2026
finance.yahoo.comArchivedNeutral tone

Should Value Investors Buy Merck KGaA (MKKGY) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits. On top of the

EarningsEarnings GrowthEstimate RevisionsInvestment StrategyValue Investing
Published
23 Jul 2026 14:40
Catalyst
Earnings
Coverage
Direct company
Duplicates
1 consolidated
Jul 18 2026
finance.yahoo.comArchivedNeutral tone

Merck KGaA (XTRA:MRK) Opens New Darmstadt Testing Site As Pipeline Progress Builds

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Merck KGaA's MilliporeSigma unit has opened a new BioReliance testing facility in Darmstadt, Germany, expanding its biopharmaceutical testing footprint in Europe. The company reported a European label update for Erbitux in colorectal cancer, reflecting regulatory progress for its oncology portfolio. Enpatoran, Merck KGaA's investigational lupus therapy, has received US FDA Breakthrough Therapy designation. Merck KGaA (XTRA:MRK) is adding fresh momentum to its healthcare and life s

BiopharmaHealthcareImmunologyInfrastructureOncologyShare Price
Published
18 Jul 2026 10:07
Catalyst
Regulatory and legal
Coverage
Direct company
Duplicates
1 consolidated

Provider matches checked

Provider mentions not used in the score

3 not scored

A news provider linked these stories to MRCK, but the headline and available text are not mainly about Merck KGaA. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of MRCK sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context